Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.
Checked against the public recordLast updated Jun 8, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Radiation Therapy Oncology Group
- Interventions being studied
- Radiation: Radiation therapy; Other: Observation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Diagnosis of stage IIIA or IIIB non-small cell lung cancer * Complete response, partial response, or stable disease after definitive locoregional therapy (with surgery and/or radiation therapy, with or without chemotherapy (chemotherapy alone does not constitute definitive therapy)) * No more than 16 weeks since prior therapy * No progressive disease * No extracranial distant metastatic disease * No suspicion of CNS metastases by MRI or CT scan PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * No other malignancy within the past 3 years except nonmelanoma skin cancer * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent anticancer biologic therapy Chemotherapy * See Disease Characteristics * No concurrent anticancer cytotoxic chemotherapy Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics * No prior cranial irradiation Surgery * See Disease Characteristics Other * Recovered from all prior therapies * No concurrent enrollment on any other phase III study that has progression-free, disease-free, or overall survival as an endpoint
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Arizona Oncology Services FoundationPhoenix, Arizona
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - OsbornScottsdale, Arizona
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - SheaScottsdale, Arizona
- Resurrection Medical CenterChicago, Illinois
- Central Maine Comprehensive Cancer Center at Central Maine Medical CenterLewiston, Maine
- Maine Center for Cancer Medicine and Blood Disorders - ScarboroughScarborough, Maine
- Shore Regional Cancer Center at Memorial Hospital - EastonEaston, Maryland
- MetroWest Medical Center - Framingham Union HospitalFramingham, Massachusetts
- Josephine Ford Cancer Center at Henry Ford HospitalDetroit, Michigan
- Cancer Institute of New Jersey at Cooper University Hospital - CamdenCamden, New Jersey
- Geisinger Cancer Institute at Geisinger HealthDanville, Pennsylvania
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical CenterWilkes-Barre, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 8, 2018. Always confirm current availability with the study team.